Huntsman Cancer Institute VanBrocklin Lab


View all publications in PubMed

A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma. 
Ray A, Williams MA, Meek SM, Bowen RC, Grossmann KF, Andtbacka RH, Bowles TL, 
Hyngstrom JR, Leachman SA, Grossman D, Bowen GM, Holmen SL, VanBrocklin MW, Suneja G, Khong HT (2016).
Oncotarget7(39), 64390-64399. 

In vitro visualization and characterization of wild type and mutant IDH homo- and heterodimers using Bimolecular Fluorescence Complementation.
Robinson GL, Philip B, Guthrie MR, Cox JE, Robinson JP, 
VanBrocklin MW, Holmen SL (2016).
Cancer Res Front2(2), 311-329. 

A Phase I trial of azacitidine and nanoparticle albumin bound paclitaxel in patients with advanced or metastatic solid tumors. 
Cohen AL, Ray A, Van Brocklin MW, Burnett DM, Bowen RC, Dyess DL, Butler TW, Dumlao T, 
Khong HT (2016).

Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma.
Yang H, Kircher DA, Kim KH, Grossmann AH, 
VanBrocklin MW, Holmen SL, Robinson JP (2017).
LID - 10.1038/onc.2016.526 [doi].Oncogene.

HBEGF promotes gliomagenesis in the context of Ink4a/Arf and Pten loss.
Shin CH, Robinson JP, Sonnen JA, Welker AE, Yu DX, 
VanBrocklin MW, Holmen SL (2017).
LID -10.1038/onc.2017.83 [doi]. (Epub ahead of print) Oncogene.

A Phase I study of Neoadjuvant Chemotherapy with Nab-Paclitaxel, Doxorubicin and Cyclophosphamide in Patients with Stage II-III Breast Cancer. 
Werner T, Ray A, Lamb J, 
VanBrocklin MW, Hueftle K, Cohen A, Beck A, Buys S, Dyess D, Butler T, Dumlao T, Neumayer L and Khong HT (In Press).
Breast Cancer Res.

Resistance mechanisms to genetic suppression of mutant NRAS in melanoma. 
Robinson JP, Rebecca VW, Kircher DA, Silvus MR, Samlley I, Gibney GT, Lastwika KJ, Chen G, 
Davies MA, Grossman D, Smalley KS, Holmen SL, and VanBrocklin MW (In Press).
Melanoma Res.

AKT1 Activation Promotes Development of Melanoma Metastases.
Cho JH, Robinson JP, Arave RA, Burnett WJ, Kircher DA, Chen G, Davies MA, Grossmann AH, VanBrocklin MW, McMahon M, Holmen SL.
Cell Rep. 2015 Nov 3;13(5):898-905. doi: 10.1016/j.celrep.2015.09.057. Epub 2015 Oct 22.

Model of the TVA Receptor Determinants Required for Efficient Infection by Subgroup A Avian Sarcoma and Leukosis Viruses.
Melder DC, Pike GM, VanBrocklin MW, Federspiel MJ
J Virol. 2015 Feb 15;89(4):2136-48. doi: 10.1128/JVI.02339-14. Epub 2014 Dec 3.

Akt signaling accelerates tumor recurrence following ras inhibition in the context of ink4a/arf loss.
Robinson GL, Robinson JP, Lastwika KJ, Holmen SL, Vanbrocklin MW.
Genes Cancer. 2013 Nov;4(11-12):476-85.